What Are The Latest Developments In Glioma Therapeutics Market.
Glioma Therapeutics Market |
Glioma is a
brain tumor that begins in the glial cells and spreads to the brain and spinal
cord. There are low-grade and high-grade glioma types. The glioma treatment
includes small molecules such as everolimus, carmustine, and temozolomide and
biologics such as bevacizumab.
As per the latest market research report published by
Technavio, the global glioma therapeutics market size will grow by USD 861.69
million during 2019-2023. Get the free sample report below for the detailed
information.
Download the free
sample report @ http://bit.ly/2pohmgz
Currently, there are only seven gene therapies
approved across the world, and these therapies have proved to be highly
effective in the treatment of various indications. Thus, companies are
conducting clinical trials for the treatment of glioma.
These studies are still
in the early phases of clinical trials. For instance, Tocagen is currently
conducting a Phase II/III study on Toca 511, a novel gene therapy that consists
of a purified retroviral replicating vector for encoding a modified yeast
cytosine deaminase (CD) gene.
Furthermore, Ad-RTS-hlL-12 is under development by
Ziopharm Oncology and is in the Phase I stage of development for the treatment
of glioma. Advances in regenerative medicine are expected to contribute
significantly to the market.
Hence, the development of gene therapy for the
treatment of glioma is expected to be a key trend in the global glioma
therapeutics market, which will grow at a CAGR of 9.34% during the forecast
period. To know the complete and in-depth analysis and
forecast of this market get the complete report by clicking the link below.
Get the Complete
Report @ http://bit.ly/31pf3XE
Comments
Post a Comment